________________________________________________________________________________________________________________________________

Stem Cells: a discovery tool and a potential therapeutic modality

September 2009. What are the needs for stem cell technologies in the pharmaceutical industry? What are the major challenges, and how can you ensure a close fit with external collaborators, like I-STEM? An interview with Dr Jonathan Knowles, at the time Member of the Roche Executive Committee and Head of Group Research.

 

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 2 pages

Full Company License enquire here

Back to section

Related Editorial Articles

Transition Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

Patient-centered Precision Care
Michael Christman, President of the Coriell Institute for Medical Research at Camden, New Jersey (US), talks about some tricky issues of turning research on genotyping into healthcare routines

Leroy Hood: Thinking Further about Stem Cells

Novartis: Preparing for another Level of Innovation
Mark Fishman, President of the Novartis Institutes for BioMedical Research (NIBR) and Member of the Executive Committee of Novartis, comments stem cell issues including technology acquisitions in the field.

Merck Serono: Clear away complete confusion of terms
Bernhard Kirschbaum, today Head of Global Research and Early Development for Merck Serono on stem cell research

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

The Myriad Way
Peter D Meldrum, CEO of the genetics company on battles about patents, cancer chips, and competitors in commercial academia

Bayer AG: New Stakes in Stem Cells
Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Patenting Stem Cells – Behind the Front Stages
The patentability of stem cells is of continuing debate. The article outlines the legal approach to stem cells as it informs solving juridical problems.

GSK: Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Boehringer Ingelheim: We are obliged to more and more move away from animal models
Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim and Head of Corporate Board Division Pharma Research Corporate, evaluates prospects for stem technologies

Drug Testing with Embryonic Stem Cells
David Hays on standardization issues for therapeutics

L'Oréal Makes Progress in Stem Cell Research

Stem Cells – Failings and Deliveries
Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital